Back To Search Results

Elimination Half-Life of Drugs

Editor: Valerie Gerriets Updated: 5/3/2025 10:44:07 PM

Definition/Introduction

In medical science, the term half-life typically refers to the elimination half-life. The elimination half-life is defined as the time required for the concentration of a specific substance, typically a drug, to decrease to half of its initial amount in the body. Understanding the concept of half-life is essential for determining excretion rates and steady-state concentrations of any specific drug. Although different drugs have varying half-lives, they all share a common principle—after one half-life, 50% of the initial drug amount is removed from the body. The characteristic decline of drug concentrations over time has long been studied in the field of pharmacokinetics and can be described using basic differential equations. Most clinically relevant drugs follow first-order pharmacokinetics, meaning their drug-elimination rates are directly proportional to plasma concentrations.[1] In contrast, a few drugs follow zero-order elimination, in which the drug amount decreases by a constant amount over time, regardless of initial concentration, for example, ethanol. This activity focuses on first-order half-life elimination as it is the most frequently encountered in clinical practice.

The half-life elimination of a drug is graphically represented by elimination curves that track the amount of the drug in the body over time, typically with time on the independent axis and drug plasma concentration on the dependent axis (see GraphHalf-Life Elimination Curve). The total drug exposure over time is represented in this graph as the area under the curve.[2] Elimination curves are useful for determining whether a drug indeed follows first-order kinetics, in which case the curve should follow a logarithmic decay according to the integrated rate law of first-order reactions (Equation 1). After the differential equation is solved, the half-life equation, commonly tested on and used in clinical practice, is obtained (Equation 2). From this equation, the half-life of a drug can be quickly determined, given its predetermined rate constant k. An alternative half-life equation exists that relates half-life to other pharmacokinetic parameters, specifically the volume of distribution and clearance (Equation 3).[3][4]

  • Equation 1: ln[A0]/[A]=kt
  • Equation 2: t1/2=0.693/k
  • Equation 3: t1/2=0.693×Vd/CL, where Vd is the volume of distribution and CL is clearance.

The relationship between the percentage of drug eliminated and the number of half-lives is also important to consider. Assuming no administration of additional drugs after an initial dose, ignoring any drug-drug interactions, and assuming a physiologically healthy individual, certain quantitative constants apply to all drugs exhibiting first-order pharmacokinetics. For example, 90% of a given drug undergoes elimination after approximately 3.3 half-lives. Moreover, 94% to 97% of a drug is eliminated after 4 to 5 half-lives. Therefore, after 4 to 5 half-lives, the plasma concentration of a given drug typically falls below a clinically relevant concentration and is considered effectively eliminated. Conversely, the accumulation of a drug can reach a steady state during an infusion. When administering a drug at regular intervals or a constant amount, such as an infusion, the drug achieves a steady-state concentration after approximately 4 to 5 half-lives, without further accumulation in the body with repeated doses.[5] This steady state occurs when the drug's infusion rate equals its clearance rate, resulting in a constant net concentration in the body. The steady-state concentration is determined by the dosage, dosing interval, and clearance.

Issues of Concern

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Issues of Concern

Half-life is one of the oldest pharmacokinetic parameters discussed in the medical community, yet it remains a source of confusion for many medical students and even experienced clinicians.[6] As a result, examiners of the United States Medical Licensing Examination regularly test and assess medical students and licensed clinicians to ensure they understand it. The concept of half-life relies on several key assumptions, including a one-compartment system for drug metabolism, a perfectly first-order system without renal or hepatic deficiencies, and an isolated system without any drug-drug interactions or alternative metabolic pathways. This situation is rarely encountered in a clinical setting where physicians treat patients with chronic kidney disease or other health issues, who may be taking multiple medications with potential drug interactions. In addition, patient age is a significant factor in determining the accurate half-life of a drug, especially in pediatric and geriatric patients, where drug metabolism, and thus, half-life, can vary significantly from that of a healthy middle-aged adult. Due to the highly theoretical nature of the half-life model, its practical application in clinical decision-making is often challenging. Therefore, medical students and clinicians must factor these realities into half-life calculations to ensure effective and safe pharmacological management. Numerous studies have attempted to establish methodologies that account for such nuances in disease management based on individual pharmacokinetic drug profiles.[7][8]

Clinical Significance

The clinical significance of half-life often emerges in situations involving drug toxicity. Such cases may arise from patient overdose, administration of incorrect drug dosages by medical staff, significant renal or hepatic impairment, or other factors that elevate plasma drug concentrations beyond toxic thresholds. In cases of renal failure, drug excretion is impaired, leading to increased peak initial concentration and excretion rate of the drug.[9] Hepatic disease also affects the half-life of a given drug due to impaired metabolism. Because the liver inactivates active metabolites at a slower rate, the body requires a longer period to eliminate the drug from circulation.[10] Half-life is also clinically relevant when clinicians must establish the most effective and safest dosing schedule to achieve an optimal therapeutic effect, or when a steady-state concentration of a drug is desirable. The frequent occurrence of these clinical scenarios explains why medical professionals consistently rely on half-life calculations in practice and why the concept remains a key focus in medical education.

Nursing, Allied Health, and Interprofessional Team Interventions

Understanding the concept of half-life is a critical first step in determining dosing schedules for pharmacological treatment. However, arguably more important is the communication of this management plan from the clinician or pharmacist to the interprofessional care team. Effective communication remains a key determinant of quality care delivery. A literature review suggests that communication skills should be heavily emphasized before healthcare professionals enter clinical settings, ensuring they master these skills during training before engaging in patient interactions.[11] Interestingly, face-to-face communication was considered the most effective method for understanding a patient's care plan completely, although written communication remains the most commonly used. However, this contrast does not mean that written communication lacks its strengths. Written communication provides a more permanent record that can be revisited if needed. In addition, the advent of electronic medical records allows for the almost instantaneous transmission of entire patient records regardless of the distance between healthcare providers, something that face-to-face communication is less suited for.

Unsurprisingly, interprofessional communication has also been correlated with patient satisfaction.[12] Conversely, poor communication has been cited as an issue in more than 80% of lawsuits, further emphasizing the critical importance of effective communication in health care. Poor communication could have occurred at any point during a patient's care, whether between a patient and a staff member, a nurse and a clinician, among clinicians, or a clinician and a patient. Due to the complexity of any individual's course through the healthcare system, strong communication is essential. From a financial perspective, Medicare uses patient satisfaction surveys to determine hospital reimbursement through pay-for-performance programs, providing a powerful incentive for healthcare professionals to prioritize effective communication with and around patients.[13] Numerous studies, including those mentioned previously, support the ongoing push to improve communication practices. This area of health care is extensively researched due to its impact on patient satisfaction with healthcare professionals, making it a top priority for hospitals and healthcare providers worldwide.

Media


(Click Image to Enlarge)
<p>Half-Life Elimination Curve

Half-Life Elimination Curve. The half-life elimination of a drug is illustrated by an elimination curve, which plots the amount of drug remaining in the body over time. Time is represented on the independent axis, whereas drug plasma concentration is represented on the dependent axis.

Chemistry LibreTexts

References


[1]

Borowy CS, Ashurst JV. Physiology, Zero and First Order Kinetics. StatPearls. 2025 Jan:():     [PubMed PMID: 29763041]


[2]

Erkent U, Koytchev R. The use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs. Studies with donepezil and memantine. Arzneimittel-Forschung. 2008:58(5):255-8. doi: 10.1055/s-0031-1296502. Epub     [PubMed PMID: 18589560]

Level 1 (high-level) evidence

[3]

Oie S. Drug distribution and binding. Journal of clinical pharmacology. 1986 Nov-Dec:26(8):583-6     [PubMed PMID: 3793947]


[4]

Toutain PL, Bousquet-Mélou A. Plasma clearance. Journal of veterinary pharmacology and therapeutics. 2004 Dec:27(6):415-25     [PubMed PMID: 15601437]

Level 3 (low-level) evidence

[5]

Ito S. Pharmacokinetics 101. Paediatrics & child health. 2011 Nov:16(9):535-6     [PubMed PMID: 23115489]


[6]

Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharmaceutical research. 2008 Dec:25(12):2869-77. doi: 10.1007/s11095-008-9787-9. Epub 2008 Nov 18     [PubMed PMID: 19015955]


[7]

Gidal BE, Clark AM, Anders B, Gilliam F. The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. Epilepsy research. 2017 Jan:129():26-32. doi: 10.1016/j.eplepsyres.2016.10.020. Epub 2016 Nov 9     [PubMed PMID: 27883934]


[8]

Gorsline J, Gupta SK, Dye D, Rolf CN. Steady-state pharmacokinetics and dose relationship of nicotine delivered from Nicoderm (Nicotine Transdermal System). Journal of clinical pharmacology. 1993 Feb:33(2):161-8     [PubMed PMID: 8440766]

Level 1 (high-level) evidence

[9]

Levy G. Pharmacokinetics in renal disease. The American journal of medicine. 1977 Apr:62(4):461-5     [PubMed PMID: 851113]


[10]

Branch RA, Herbert CM, Read AE. Determinants of serum antipyrine half-lives in patients with liver disease. Gut. 1973 Jul:14(7):569-73     [PubMed PMID: 4729926]


[11]

Vermeir P, Vandijck D, Degroote S, Peleman R, Verhaeghe R, Mortier E, Hallaert G, Van Daele S, Buylaert W, Vogelaers D. Communication in healthcare: a narrative review of the literature and practical recommendations. International journal of clinical practice. 2015 Nov:69(11):1257-67. doi: 10.1111/ijcp.12686. Epub 2015 Jul 6     [PubMed PMID: 26147310]

Level 3 (low-level) evidence

[12]

Lang EV. A Better Patient Experience Through Better Communication. Journal of radiology nursing. 2012 Dec 1:31(4):114-119     [PubMed PMID: 23471099]


[13]

Anhang Price R, Elliott MN, Zaslavsky AM, Hays RD, Lehrman WG, Rybowski L, Edgman-Levitan S, Cleary PD. Examining the role of patient experience surveys in measuring health care quality. Medical care research and review : MCRR. 2014 Oct:71(5):522-54. doi: 10.1177/1077558714541480. Epub 2014 Jul 15     [PubMed PMID: 25027409]

Level 2 (mid-level) evidence